Reports of Elevidys Deaths Linked to Sarepta’s Gene Therapy

In June 2024, Sarepta Therapeutics voluntarily paused dosing in its clinical trials of Elevidys—a gene therapy for Duchenne muscular dystrophy—after a patient died during the trial. While details remain limited, the FDA was promptly notified, and Sarepta has acknowledged the “serious safety event” that triggered the halt.

Reports of Elevidys Deaths Linked to Sarepta’s Gene Therapy